Nanjing Vazyme Biotech (688105) Stock Overview

Nanjing Vazyme Biotech Co., Ltd. offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers reagents for molecular biology research, such as nucleic acid extraction, PCR, cloning/mutagenesis, nucleic acid electrophoresis, reverse transcription, real-time PCR (qPCR), genome editing, and cell biology/protein research; reagents for NGS library preparation, including automated liquid handling workstation, DNA sequencing, RNA sequencing, single cell-seq series, epigenetics series, beads series, quantification series, and capture series; reagents for molecular diagnosis comprising isothermal amplification reagents, PCR, reverse transcription, real-time PCR, one-step series, and animal detection; and reagents for bio-medicine, such as vaccine effectiveness evaluations and vaccine manufacture. Nanjing Vazyme Biotech Co., Ltd. was founded in 2012 and is based in Nanjing, China.